Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines.

Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:43-62. doi: 10.1016/j.jbior.2018.05.002. Epub 2018 May 18.

PMID:
29861174
2.

Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z.

Cancer Res. 2017 May 15;77(10):2647-2660. doi: 10.1158/0008-5472.CAN-16-1986. Epub 2017 Mar 1.

3.

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.

Chakraborty SN, Leng X, Perazzona B, Sun X, Lin YH, Arlinghaus RB.

Genes Cancer. 2016 May;7(5-6):201-208. doi: 10.18632/genesandcancer.111.

4.

Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.

Mu C, Wu X, Ma H, Tao W, Zhang G, Xia X, Shen J, Mai J, Sun T, Sun X, Arlinghaus RB, Shen H.

Mol Cancer Ther. 2016 May;15(5):899-910. doi: 10.1158/1535-7163.MCT-15-0577-T. Epub 2016 Feb 4.

5.
6.

Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.

Mallampati S, Leng X, Ma H, Zeng J, Li J, Wang H, Lin K, Lu Y, Yang Y, Sun B, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, Cai Z, Fang B, Shen H, Han X, Hirsch-Ginsberg CF, Gao X, Paranjape AN, Mani SA, Clise-Dwyer K, Sun X.

Blood. 2015 May 7;125(19):2968-73. doi: 10.1182/blood-2014-05-576421. Epub 2015 Feb 23.

7.

The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.

Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin CC, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantarjian HM, Arlinghaus RB, Glassman A, Sun X.

Haematologica. 2014 Oct;99(10):1591-8. doi: 10.3324/haematol.2014.104695. Epub 2014 Jul 4.

8.

c-Abl activates janus kinase 2 in normal hematopoietic cells.

Tao W, Leng X, Chakraborty SN, Ma H, Arlinghaus RB.

J Biol Chem. 2014 Aug 1;289(31):21463-72. doi: 10.1074/jbc.M114.554501. Epub 2014 Jun 12.

9.

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.

Chakraborty S, Lin YH, Leng X, Miranda RN, Medeiros LJ, Shpall E, Arlinghaus RB.

Blood Cancer J. 2013 Sep 6;3:e142. doi: 10.1038/bcj.2013.41. No abstract available.

10.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

11.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D.

Blood. 2013 Sep 12;122(11):1923-34. doi: 10.1182/blood-2013-03-492181. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

12.

Multiplexed volumetric bar-chart chip for point-of-care diagnostics.

Song Y, Zhang Y, Bernard PE, Reuben JM, Ueno NT, Arlinghaus RB, Zu Y, Qin L.

Nat Commun. 2012;3:1283. doi: 10.1038/ncomms2292.

13.

Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73.

Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, Suzuki F, Arlinghaus RB, Liu J, Mobley JA, Grizzle WE, Wang H, Sen S.

Cancer Cell. 2012 Feb 14;21(2):196-211. doi: 10.1016/j.ccr.2011.12.025.

14.

Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.

Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J.

Cancer. 2012 Jul 1;118(13):3433-45. doi: 10.1002/cncr.26621. Epub 2011 Dec 2.

15.

Relationships of lipocalin 2 with breast tumorigenesis and metastasis.

Leng X, Wu Y, Arlinghaus RB.

J Cell Physiol. 2011 Feb;226(2):309-14. doi: 10.1002/jcp.22403. Review.

PMID:
20857428
16.

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).

Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB.

Genes Cancer. 2010 Apr;1(4):346-59. doi: 10.1177/1947601910372232.

17.

A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Jatiani SS, Cosenza SC, Reddy MV, Ha JH, Baker SJ, Samanta AK, Olnes MJ, Pfannes L, Sloand EM, Arlinghaus RB, Reddy EP.

Genes Cancer. 2010 Apr;1(4):331-45. doi: 10.1177/1947601910371337.

18.

WITHDRAWN: Requirement of lipocalin 2 in breast cancer.

Leng X, Ding T, Lin H, Wang Y, Wu Y, Arlinghaus RB.

Adv Enzyme Regul. 2009 Nov 13. [Epub ahead of print] No abstract available.

PMID:
19914274
19.

Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB.

Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3.

20.

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.

Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM.

J Cell Mol Med. 2010 Jun;14(6B):1777-92. doi: 10.1111/j.1582-4934.2009.00795.x. Epub 2009 Jun 5.

21.

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, Perrotti D, Arlinghaus RB.

Oncogene. 2009 Apr 9;28(14):1669-81. doi: 10.1038/onc.2009.7. Epub 2009 Feb 23.

22.

Tissue-resident stem cells promote breast cancer growth and metastasis.

Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, Seidensticker M, Ricke J, Altman AM, Devarajan E, Liu W, Arlinghaus RB, Alt EU.

Carcinogenesis. 2009 Apr;30(4):589-97. doi: 10.1093/carcin/bgp036. Epub 2009 Jan 30.

PMID:
19181699
23.

Preparation and application of polyclonal and monoclonal sequence-specific anti-phosphoamino acid antibodies.

Sun T, Arlinghaus RB.

Curr Protoc Protein Sci. 2004 Feb;Chapter 13:Unit 13.6. doi: 10.1002/0471140864.ps1306s34.

PMID:
18429250
24.

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P.

Leukemia. 2008 Jun;22(6):1191-9. doi: 10.1038/leu.2008.74. Epub 2008 Apr 3.

25.

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.

Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J.

Blood. 2008 Mar 1;111(5):2904-8. doi: 10.1182/blood-2007-05-091769. Epub 2008 Jan 7.

26.

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P.

Cancer Cell. 2006 Sep;10(3):241-52.

27.

Janus kinase 2: a critical target in chronic myelogenous leukemia.

Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB.

Cancer Res. 2006 Jul 1;66(13):6468-72.

28.

Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.

Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB.

Oncogene. 2006 Jul 27;25(32):4483-90. Epub 2006 Mar 20.

PMID:
16547503
29.

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.

Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M.

Cancer. 2005 Sep 15;104(6):1230-6.

30.

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M.

Clin Cancer Res. 2005 Jul 1;11(13):4941-7.

31.

Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.

Ling X, Arlinghaus RB.

Cancer Res. 2005 Apr 1;65(7):2532-6. Erratum in: Cancer Res. 2005 Jun 1;65(11):4969.

32.

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S.

Nat Genet. 2004 Jan;36(1):55-62. Epub 2003 Dec 14.

PMID:
14702041
33.

Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.

Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, Mendez R, Dai JL.

Cancer Res. 2003 Aug 1;63(15):4724-30. Erratum in: Cancer Res. 2003 Oct 15;63(20):7004.

34.

The c-Myc Oncoprotein Interacts with Bcr.

Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, Arlinghaus RB, Whitehead IP.

Curr Biol. 2003 Mar 4;13(5):437-41.

35.

Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.

Ling X, Ma G, Sun T, Liu J, Arlinghaus RB.

Cancer Res. 2003 Jan 15;63(2):298-303.

36.

Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.

Arlinghaus RB.

Oncogene. 2002 Dec 9;21(56):8560-7. Review.

37.

Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.

Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB.

Leukemia. 2002 Dec;16(12):2447-53.

38.

Jak2 is involved in c-Myc induction by Bcr-Abl.

Xie S, Lin H, Sun T, Arlinghaus RB.

Oncogene. 2002 Oct 17;21(47):7137-46.

39.

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.

Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB.

Cancer. 2002 May 1;94(9):2416-25.

40.

Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient.

Lin H, Guo JQ, Andreeff M, Arlinghaus RB.

Leukemia. 2002 Feb;16(2):294-7. No abstract available.

41.

Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.

Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB.

Cancer Res. 2002 Jan 15;62(2):386-90.

42.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
43.

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.

Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE, Arlinghaus RB.

Oncogene. 2001 Sep 27;20(43):6188-95.

44.

Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.

Kardinal C, Konkol B, Lin H, Eulitz M, Schmidt EK, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM.

Blood. 2001 Sep 15;98(6):1773-81.

PMID:
11535511
45.

Preparation and application of antibodies to phosphoamino acid sequences.

Sun T, Campbell M, Gordon W, Arlinghaus RB.

Biopolymers. 2001;60(1):61-75.

PMID:
11376433
46.

BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.

Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, Belmont J, Arlinghaus RB.

Oncogene. 2001 Apr 5;20(15):1873-81.

47.

Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.

Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M.

Br J Haematol. 2001 Mar;112(3):749-59.

PMID:
11260080
48.

Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.

Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB.

Cancer Res. 2001 Jan 1;61(1):138-44.

49.

Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.

Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM.

FASEB J. 2000 Aug;14(11):1529-38.

PMID:
10928987
50.

Bcr: a negative regulator of the Bcr-Abl oncoprotein.

Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB.

Oncogene. 1999 Aug 5;18(31):4416-24.

Supplemental Content

Loading ...
Support Center